Novartis receives FDA approval for Flucelvax®, the first cell-culture vaccine in US to help protect against seasonal influenza

Novartis receives FDA approval for Flucelvax®, the first cell-culture vaccine in US to help protect against seasonal influenza Cell-culture technology, an alternative to traditional egg-based production, is the most significant advancement in influenza vaccine manufacturing in more than 40 years[1] Flucelvax is the only influenza vaccine of its kind in the US and does not contain any preservatives, such as …

Design of a “Universal” Influenza Synthetic Peptide Vaccine.

  With the influenza season quickly approaching, how important is it to produce a universal flu vaccine? How effective could a universal vaccine against subtypes of flu? Tell us below or download this presentation to find out more! Robert S. Hodges from the Department of Biochemistry & Molecular Genetics, University of Colorado School of Medicine, joined us at the World …